31/07/2025 MaxCyte and Anocca AB signed a Strategic Platform Licensing Agreement to advance TCR-T cell therapies (Ref) MaxCyte signed a Strategic Platform License Agreement (SPL) with Anocca AB in which Anocca AB will deploy MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the scalable development and manufacturing of its TCR-T cell therapy pipeline. Anocca AB obtained non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Elect